HemaCore
Moscow
About HemaCore
HemaCore was founded in 2010 as a biotech company focused on developing, manufacturing and implementing into clinical practice new in vitro diagnostic technology for hemostasis - thrombodynamics. Thrombodynamics assay – an innovative coagulation test for risk assessment of blood coagulation disorders – bleedings and thrombosis. Value proposition: they help clinicians succeed, providing clear and reliable estimation of patients coagulation state, thus giving an ability to prevent thrombotic or bleeding complications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: Less than $1M
- Last round: Series Unknown (Apr 2010)
- Website: hemacore.com
- Phone: 7 495 258 2538
Industries & Categories
Biotechnology, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/hemacore-2981965 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.